<?xml version="1.0" encoding="UTF-8"?>
<p id="p0140">Hydroxychloroquine, a disease-modifying antirheumatic drug, has been considered as a potential option to treat patients infected with COVID-19 who demonstrate cytokine storm because of its ability to sequester both innate and adaptive immunity, making it a powerful anti-inflammatory agent (
 <xref rid="b0375" ref-type="bibr">Schrezenmeier and DÃ¶rner, 2020</xref>). This agent provides a similar benefit in systemic lupus erythematous by attenuating the proinflammatory cascade (
 <xref rid="b0395" ref-type="bibr">Tang et al., 2012</xref>). A nonrandomized clinical trial combining azithromycin and hydroxychloroquine initially showed promising therapeutic potential (
 <xref rid="b0165" ref-type="bibr">Gautret et al., 2020</xref>). The authors recommended risk stratification because the combination of drugs can potentiate cardiac arrythmias. Most recently, hydroxychloroquine has fallen out of favor as a therapy of choice because of its significant side effect profile and lack of clear clinical benefit, followed by the retraction of a 
 <italic>Lancet</italic> article supporting hydroxychloroquine (
 <xref rid="b0090" ref-type="bibr">Chorin et al., 2020</xref>, 
 <xref rid="b0290" ref-type="bibr">Mehra et al., 2020</xref>).
</p>
